135 results on '"Carbonnel F"'
Search Results
2. P510 Relapse rate following withdrawal of vedolizumab and ustekinumab in patients with inflammatory bowel disease. The VEDUST-EXIT study
3. P900 A PROOF-OF-CONCEPT, PLACEBO-RANDOMIZED CONTROLLED TRIAL TARGETING ADHERENT AND INVASIVE ESCHERICHIA COLI (AIEC) WITH ANTIBIOTICS IN CROHN’S DISEASE: the TEOREM TRIAL
4. P663 Efficacy of jak inhibitors in inflammatory bowel disease patients with extraintestinal manifestations– Retrospective study
5. P470 Evolution of asymptomatic unresected lesions in patients operated for multifocal Crohn’s disease
6. P361 Risk of persistent gastrointestinal inflammation after treatment with immune checkpoint inhibitors
7. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
8. Étude rétrospective de la mise en place du certificat de compétences cliniques (C3) au format ECOS (examen clinique objectif structuré) au sein d’une faculté de médecine française
9. CONCEVOIR UNE STATION ECOS
10. P628 Processed and ultra-processed food and risk of Inflammatory Bowel Disease in the European Prospective Investigation into Cancer and Nutrition cohort (EPIC-IBD)
11. ORGANISER UN CIRCUIT ECOS
12. COMBIO : efficacité et tolérance des associations de thérapies ciblées chez les patients atteints de maladies inflammatoires à médiation immunitaire
13. P272 Tofacitinib as salvage therapy for patients hospitalized with refractory severe active ulcerative colitis: a GETAID multicenter prospective/retrospective cohort
14. P115 Chronic pouchitis and Crohn’s disease of the pouch after ileal pouch-anal anastomosis: incidence and risk factors
15. QUELS SONT LES DOMAINES DE PREVENTION LES PLUS FREQUEMMENT OUBLIES DANS LES CONSULTATIONS AVEC LES ADOLESCENTS ET LES JEUNES ADULTES ? UNE ETUDE TRANSVERSALE AUXILIAIRE ECOGEN
16. Maladie de Crohn: que faire quand tout a échoué?
17. De la bonne prise en charge des poussées graves de RCH
18. Évaluation non invasive de la fibrose hépatique chez des patients atteints de psoriasis, polyarthrite rhumatoïde ou maladie de Crohn traités par méthotrexate
19. THU0382 ARTICULAR MANIFESTATIONS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES TREATED WITH ANTI-TNFΑ
20. DOP80 Effectiveness of ustekinumab and vedolizumab in patients with Crohn’s disease refractory to anti-tumour necrosis factor: A multi-centre comparative study
21. P449 Systematic review with meta-analysis: risk of lymphoma associated with anti-tumour necrosis factor (TNF) agents in inflammatory bowel disease
22. OP17 Protein intakes and risk of inflammatory bowel disease in the European Prospective Investigation into Cancer and Nutrition cohort (EPIC-IBD)
23. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab
24. Factors associated with mechanical and systemic adverse events after colonoscopy (France, 2010-2015)
25. Systemic gut microbial metabolites limit the anti-tumour effect of CTLA-4 blockade in hosts with cancer
26. DOP40 Effectiveness and safety of reference infliximab and biosimilar in Crohn’s disease: a French equivalence study
27. P715 Real-world tofacitinib effectiveness and safety in patients with refractory ulcerative colitis
28. Complications digestives de l’immunothérapie des cancers
29. Corrections to “Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
30. Circulating plasma phospholipid fatty acids and risk of pancreatic cancer in a large European cohort
31. Comment l’urologue et son réseau de soin peuvent prendre en charge la toxicité des immunothérapies ? Application aux toxicités digestives
32. Ontologie des interventions non médicamenteuses
33. P474 Efficacy and safety of anti-TNF and vedolizumab in liver transplant recipients with inflammatory bowel disease (IBD)
34. P402 Interstitial and granulomatous lung disease in inflammatory bowel disease patients
35. P347 Vedolizumab for primary sclerosing cholangitis associated with inflammatory bowel disease: A multicentre cohort study from the GETAID
36. P366 Long-term evolution of gastrointestinal immune-related adverse events (GI-IrAE) induced by immune checkpoint inhibitors (ICI)
37. P664 Association between pharmacologic loss of response profile of anti-TNF and clinical outcome with vedolizumab
38. Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies
39. Baseline gut microbiota in metastatic melanoma patients treated with ipilimumab: Relation with clinical response and colitis
40. Letter: sprue-like enteropathy associated with angiotensin II receptor blockers other than olmesartan-authors'reply
41. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
42. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab
43. The accuracy of preoperative imaging in measuring the length of the ileocolic segment affected by Crohn's disease: a prospective cohort study
44. Erratum: No association of alcohol use and the risk of ulcerative colitis or Crohn’s disease: data from a European Prospective cohort study (EPIC)
45. P315 Gastrointestinal immune related adverse events associated with programmed-Death 1 blockade
46. P140 Use of vedolizumab in a transplanted liver patient: a case report of the first experience in a liver transplant referral center in Argentina
47. P722 Prediagnostic serum vitamin D levels and risk of inflammatory bowel disease: a pan-European, nested case-control study
48. No association of alcohol use and the risk of ulcerative colitis or Crohn’s disease: data from a European Prospective cohort study (EPIC)
49. Long-term outcome of patients with steroid-refractory acute severe UC treated with ciclosporin or infliximab
50. L’approche centrée patient améliore et facilite la détection de la vulnérabilité sociale. Analyse qualitative phénoménologique
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.